Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ699,5700,50,00
KB846,5849-1,74
PKN74,8275,04-1,42
Msft-1,75
Nokia4,7024,747-2,15
IBM-0,88
Daimler AG7171,02-1,07
PFE-1,30
20.09.2021 9:06:59
Indexy online
AD Index online
select
AD Index online
 

  • 17.09.2021
Corcept Thera (NASDAQ Cons)
Závěr k 17.9.2021 Změna (%) Změna (USD) Objem obchodů (ks)
20,51 -0,58 -0,12 2 000 805
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 20.09.2021
Popis společnosti
Obecné informace
Název společnostiCorcept Therapeutics Incorporated
TickerCORT
Kmenové akcie:Ordinary Shares
RICCORT.O
ISIN-
Poslední známé roční výsledky31.12.2020
Poslední známé čtvrtletní výsledky30.06.2021
Počet zaměstnanců k 31.12.2020 236
Akcie v oběhu k 22.07.2021 115 926 629
MěnaUSD
Konstituent indexůS&P 600 Small Cap
Kontaktní informace
Ulice149 Commonwealth Dr
MěstoMENLO PARK
PSČ94025-1133
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 503 273 270
Fax16503273218

Business Summary: Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.
Financial Summary: BRIEF: For the six months ended 30 June 2021, CorceptTherapeutics Incorporated revenues decreased 6% to $171M.Net income decreased 14% to $50M. Revenues reflect adecrease in demand for the Company's products and servicesdue to unfavorable market conditions. Net income alsoreflects Other Selling,General & Administrative increase of9% to $45.7M (expense), Selling, General And AdministrativeExpe increase of 26% to $13.8M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Pharmaceuticals (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 20.09.2021
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, Co-Founder, DirectorJoseph Belanoff6301.01.201401.01.1999
Chief Financial Officer, TreasurerAtabak Mokari4401.03.202101.03.2021
Chief Accounting OfficerJoseph Lyon4313.07.202001.01.2012
Chief Scientific OfficerHazel Hunt6101.07.202001.07.2020
Chief Development OfficerWilliam Guyer-16.08.202116.08.2021
Chief Commercial OfficerSean Maduck4401.07.2020
Chief Business Officer, SecretaryGary Robb5801.03.202101.09.2011